Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest.
説明 | LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest. |
ターゲット&IC50 | Tubulin polymerization:3.2 μM (EC50) |
In vitro | LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. LP-261 was also used in combination with bevacizumab in the SW620 xenograft model. LP-261 also exhibited high oral bioavailability and apparent lack of efflux by intestinal transporters such as ABCB1. LP-261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft model and shown to be schedule dependent. Excellent inhibition of tumor growth in the SW620 model was observed, comparable with paclitaxel[1]. |
In vivo | LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model[2]. |
分子量 | 421.47 |
分子式 | C22H19N3O4S |
CAS No. | 915412-67-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22 mg/ml (52.20 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LP-261 915412-67-8 Cytoskeletal Signaling Microtubule Associated NCI-H522 tubulin polymerization tumor SW-620 BXPC-3 H522 anti-mitotic LP261 inhibit LP 261 MCF-7 Inhibitor Microtubule/Tubulin cancer Jurkat inhibitor